Objective To study the effect of ISO-1 [(S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester], a specific antagonist of MIF (Macrophage migration inhibition factor), on TLR4 (Toll-like receptor) activities in HUVEC (Human umbilical vein endothelial cells), and to provide an experimental evidence for the treatment of TLR4-related diseases in which ISO-1 is targeted at. Methods HUVECs were cultured and divided into 4 groups: LPS (lipid polysaccharide) group, ISO-1 pretreatment group, LPS+ISO-1 group and Medium control group. Effects of ISO-1 on TLR4 expression, TNFα (tumor necrosis factor) and NOS (nitric oxide synthase ) secretion were investigated with RT-PCR, immunofluorescense staining, radioimmunoassay and enzyme-chemical reactions. Results The expression of TLR4 in HUVEC was obviously inhibited by pretreatment with high concentration of ISO-1, especially in 25 and 50μmol/L groups (P<0.05). Low expression of TLR4 was also detected at 0.5, 1, 2 and 3h after the pretreatment with 50μmol/L ISO-1, in which the lowest appeared at 1h (P<0.05) . Immunofluorescense showed low level TLR4 in normal HUVEC, however, the expression could be enhanced by LPS (10ng/mL). TLR4 expression, TLR4-induced TNFα and NOS secretion were markedly suppressed 1h later after the pretreatment with 50μmol/L ISO-1, and such inhibition was does-dependent (P<0.05). The effective time of ISO-1 was short and the maximal was at 1h. Conclusion ISO-1 can exert the inhibitory effects through down-regulating the TLR4 activities of HUVEC, which suggests that ISO-1 may be a potential target-agent in the treatment of TLR4-related diseases, such as atherosclerosis and inflammation.